Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus

Current Pharmaceutical Design

Volumn 13, Issue 19, 2007, Pages 1975-1988

  Ferenczy, Michael W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine adjuvant; DNA vaccine; HSV 1; Therapeutic vaccine

Indexed keywords

ALUMINUM SALT; ANTHRAX VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CHICKENPOX VACCINE; CYTOKINE; DISABLED INFECTIOUS SINGLE CYCLE VACCINE; DNA VACCINE; GLYCOSAMINOGLYCAN; HERPES SIMPLEX VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MEMBRANE PROTEIN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RECOMBINANT HEPATITIS B VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ANTHRAX; CELLULAR IMMUNITY; CHICKENPOX; CLINICAL TRIAL; CYTOKINE PRODUCTION; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; MOLECULAR BIOLOGY; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL; TREATMENT PLANNING; VIRAL GENE DELIVERY SYSTEM; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION;

ANIMALS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HUMANS; SIMPLEXVIRUS; TECHNOLOGY, PHARMACEUTICAL;

EID: 34447254981     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781039779     Document Type: Review

References (210)

1. Pepose JS, Leib DA, Stuart PM, Easty DL. Herpes simplex virus diseases: anterior segment of the eye. In: Pepose JS, Holland GN, Wilhelmus KR, Eds. Ocular Infection & Immunity. St. Louis: Mosby 1996; xl, 1552 p.
2. Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev 1997; 10(3): 521-67.
3. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988; 1(8594): 1065-7.
4. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266(5192): 1865-9.
5. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86(4): 1276-80.
6. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332(18): 1186-91.
7. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88(2): 645-56.
8. Albrecht D, Meyer T, Lorenzen T, Stoehr A, Arndt R, Plettenberg A. Epidemiology of HHV-8 infection in HIV-positive patients with and without Kaposi sarcoma: diagnostic relevance of serology and PCR. J Clin Virol 2004; 30(2): 145-9.
9. Fields BN, Knipe DM, Howley PM, Griffin DE. Fields' virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins 2001.
10. Rajcani J, Andrea V, Ingeborg R. Peculiarities of herpes simplex virus (HSV) transcription: an overview. Virus Genes 2004; 28(3): 293-310.
11. Mori I, Nishiyama Y. Herpes simplex virus and varicella-zoster virus: why do these human alphaherpesviruses behave so differently from one another? Rev Med Virol 2005; 15(6): 393-406.
12. Ku CC, Besser J, Abendroth A, Grose C, Arvin AM. Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005; 79(5): 2651-8.
13. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4(10): 757-68.
14. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4(12): 725-38.
15. Ward KN. The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in the immunocompetent. J Clin Virol 2005; 32(3): 183-93.
16. Schulz TF. The pleiotropic effects of Kaposi's sarcoma herpesvirus. J Pathol 2006; 208(2): 187-98.
17. Roizman B, Sears AE. Herpes simplex viruses and their replication. In: Fields BN, Knipe DM, Howley PM, Griffin DE, Eds. Fields' Virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins 2001; 2231-95.
18. Ali SA, McLean CS, Boursnell ME, Martin G, Holmes CL, Reeder S, et al. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. Cancer Res 2000; 60(6): 1663-70.
19. Whitley RJ. Herpes simplex viruses. In: Fields BN, Knipe DM, Howley PM, Griffin DE, Eds. Fields' virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins 2001; 2461-342.
20. Kaufman H, Rayfield M, Gebhardt B. Herpes simplex viral infections. In: Kaufman H, Barron B, McDonald M, Eds. The cornea. New York: Churchill Livingstone 1988; 247-78.
21. Knotts FB, Cook ML, Stevens JG. Pathogenesis of herpetic encephalitis in mice after ophthalmic inoculation. J Infect Dis 1974; 130(1): 16-27.
22. Whitley RJ, Gnann JW Jr. The epidemiology and clinical manifestations of herpes simplex virus infections. In: Roizman B, Whitley RJ, Lopez C, Eds. The human herpesviruses. New York: Raven Press 1993; p. 69-105.
23. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001; 20(1): 1-13.
24. Black FL. Infectious diseases in primitive societies. Science 1975; 187(4176): 515-8.
25. Liedtke W, Opalka B, Zimmermann CW, Lignitz E. Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. J Neurol Sci 1993; 116(1): 6-11.
26. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26(3): 541-53; quiz 54-5.
27. Schacker T. The role of HSV in the transmission and progression of HIV. Herpes 2001; 8(2): 46-9.
28. Liddon N, Pulley L, Cockerham WC, Lueschen G, Vermund SH, Hook EW. Parents/guardians' willingness to vaccinate their children against genital herpes. J Adolesc Health 2005; 37(3): 187-93.
29. Zimet GD, Perkins SM, Sturm LA, Bair RM, Juliar BE, Mays RM. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 2005; 37(3): 179-86.
30. Gruenheid S, Gatzke L, Meadows H, Tufaro F. Herpes simplex virus infection and propagation in a mouse L cell mutant lacking heparan sulfate proteoglycans. J Virol 1993; 67(1): 93-100.
31. WuDunn D, Spear PG. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 1989; 63(1): 52-8.
32. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998; 280(5369): 1618-20.
33. Campadelli-Fiume G, Cocchi F, Menotti L, Lopez M. The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells. Rev Med Virol 2000; 10(5): 305-19.
34. Honess RW, Roizman B. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 1974; 14(1): 8-19.
35. Honess RW, Roizman B. Regulation of herpesvirus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional viral polypeptides. Proc Natl Acad Sci USA 1975; 72(4): 1276-80.
36. Batterson W, Roizman B. Characterization of the herpes simplex virion-associated factor responsible for the induction of alpha genes. J Virol 1983; 46(2): 371-7.
37. Campbell ME, Palfreyman JW, Preston CM. Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J Mol Biol 1984; 180(1): 1-19.
38. Gaffney DF, McLauchlan J, Whitton JL, Clements JB. A modular system for the assay of transcription regulatory signals: the sequence TAATGARAT is required for herpes simplex virus immediate early gene activation. Nucleic Acids Res 1985; 13(21): 7847-63.
39. Watson RJ, Clements JB. A herpes simplex virus type 1 function continuously required for early and late virus RNA synthesis. Nature 1980; 285(5763): 329-30.
40. Jackson SA, DeLuca NA. Relationship of herpes simplex virus genome configuration to productive and persistent infections. Proc Natl Acad Sci USA 2003; 100(13): 7871-6.
41. Deshmane SL, Fraser NW. During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. J Virol 1989; 63(2): 943-7.
42. Herrera FJ, Triezenberg SJ. VP16-dependent association of chromatin-modifying coactivators and underrepresentation of histones at immediate-early gene promoters during herpes simplex virus infection. J Virol 2004; 78: 9689-96.
43. Kent JR, Zeng PY, Atanasiu D, Gardner J, Fraser NW, Berger SL. During lytic infection herpes simplex virus type 1 is associated with histones bearing modifications that correlate with active transcription. J Virol 2004; 78: 10178-86.
44. Leinbach SS, Summers WC. The structure of herpes simplex virus type 1 DNA as probed by micrococcal nuclease digestion. J Gen Virol 1980; 51: 45-59.
45. Muggeridge MI, Fraser NW. Chromosomal organization of the herpes simplex virus genome during acute infection of the mouse central nervous system. J Virol 1986; 59: 764-7.
46. Hobbs WE 2nd, DeLuca NA. Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J Virol 1999; 73(10): 8245-55.
47. Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003; 18: 593-603.
48. Spivack JG, Fraser NW. Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection. J Virol 1988; 62(5): 1479-85.
49. Spivack JG, Fraser NW. Expression of herpes simplex virus type 1 (HSV-1) latency-associated transcripts and transcripts affected by the deletion in avirulent mutant HFEM: evidence for a new class of HSV-1 genes. J Virol 1988; 62(9): 3281-7.
50. Tomishima MJ, Smith GA, Enquist LW. Sorting and transport of alpha herpesviruses in axons. Traffic 2001; 2(7): 429-36.
51. Blondeau JM, Aoki FY, Glavin GB. Stress-induced reactivation of latent herpes simplex virus infection in rat lumbar dorsal root ganglia. J Psychosom Res 1993; 37(8): 843-9.
52. Tal-Singer R, Lasner TM, Podrzucki W, Skokotas A, Leary JJ, Berger SL, et al. Gene expression during reactivation of herpes simplex virus type 1 from latency in the peripheral nervous system is different from that during lytic infection of tissue cultures. J Virol 1997; 71: 5268-76.
53. Lafferty WE. The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes 2002; 9(2): 51-5.
54. Aguilar JS, Devi-Rao GV, Rice MK, Sunabe J, Ghazal P, Wagner EK. Quantitative comparison of the HSV-1 and HSV-2 transcriptomes using DNA microarray analysis. Virology 2006; 348: 233-41.
55. Dolan A, Jamieson FE, Cunningham C, Barnett BC, McGeoch DJ. The genome sequence of herpes simplex virus type 2. J Virol 1998; 72(3): 2010-21.
56. Coleman RM, Pereira L, Bailey PD, Dondero D, Wickliffe C, Nahmias AJ. Determination of herpes simplex virus type-specific antibodies by enzyme-linked immunosorbent assay. J Clin Microbiol 1983; 18(2): 287-91.
57. Balachandran N, Oba DE, Hutt-Fletcher LM. Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. J Virol 1987; 61(4): 1125-35.
58. Nahmias AJ, Dowdle WR. Antigenic and biologic differences in herpesvirus hominis. Prog Med Virol 1968; 10: 110-59.
59. Schneweis KE, Nahmias AJ. Antigens of Herpes simplex virus type 1 and 2-immunodiffusion and inhibition passive hemagglutination studies. Z Immunitatsforsch Exp Klin Immunol 1971; 141(5): 471-87.
60. Breinig MK, Kingsley LA, Armstrong JA, Freeman DJ, Ho M. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. J Infect Dis 1990; 162(2): 299-305.
61. Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley RL, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337(8): 509-15.
62. Bryson Y, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J Infect Dis 1993; 167(4): 942-6.
63. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341(19): 1432-8.
64. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116(3):197-202.
65. Koutsky LA, Ashley RL, Holmes KK, Stevens CE, Critchlow CW, Kiviat N, et al. The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. Sex Transm Dis 1990; 17(2): 90-4.
66. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1990; 69: 19-36.
67. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, et al. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006; 177: 8658-66.
68. Hirsch RL. The complement system: its importance in the host response to viral infection. Microbiol Rev 1982; 46(1): 71-85
69. Chang YJ, Jiang M, Lubinski JM, King RD, Friedman HM. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains. Vaccine 2005; 23(38): 4658-65.
70. Da Costa XJ, Brockman MA, Alicot E, Ma M, Fischer MB, Zhou Y, et al. Humoral response to herpes simplex virus is complement-dependent. Proc Natl Acad Sci USA 1999; 96(22):12708-12.
71. Verschoor A, Brockman MA, Knipe DM, Carroll MC. Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. J Immunol 2001; 167(5): 2446-51.
72. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/ beta-producing cells link innate and adaptive immunity. J Exp Med 2000; 192(2): 219-26.
73. LaVail JH, Johnson WE, Spencer LC. Immunohistochemical identification of trigeminal ganglion neurons that innervate the mouse cornea: relevance to interceltular spread of herpes simplex virus. J Comp Neurol 1993; 327(1): 133-40.
74. Kodukula P, Liu T, Rooijen NV, Jager MJ, Hendricks RL. Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J Immunol 1999; 162(5): 2895-905.
75. Meyers-Elliott RH, Chitjian PA. Immunopathogenesis of corneal inflammation in herpes simplex virus stromal keratitis: role of the polymorphonuclear leukocyte. Invest Ophthalmol Vis Sci 1981; 20(6): 784-98.
76. Watanabe D, Adachi A, Tomita Y, Yamamoto M, Kobayashi M, Nishiyama Y. The role of polymorphonuclear leukocyte infiltration in herpes simplex virus infection of murine skin. Arch Dermatol Res 1999; 291(1): 28-36.
77. Liu T, Tang Q, Hendricks RL. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J Virol 1996; 70(1): 264-71.
78. Bukowski JF, Morita CT, Brenner MB. Recognition and destruction of virus-infected cells by human gamma delta CTL. J Immunol 1994; 153(11): 5133-40.
79. Johnson RM, Lancki DW, Sperling AI, Dick RF, Spear PG, Fitch FW, et al. A murine CD4-, CD8- T cell receptor-gamma delta T lymphocyte clone specific for herpes simplex virus glycoprotein I. J Immunol 1992; 148(4): 983-8.
80. Selin LK, Santolucito PA, Pinto AK, Szomolanyi-Tsuda E, Welsh RM. Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells. J Immunol 2001; 166(11): 6784-94.
81. Carr DJ, Harle P, Gebhardt BM. The immune response to ocular herpes simplex virus type 1 infection. Exp Biol Med (Maywood) 2001; 226(5): 353-66.
82. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 2003; 10(11): 983-90.
83. Ank N, Petersen K, Malmgaard L, Mogensen SC, Paludan SR. Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2. J Virol 2005; 79(15): 9831-41.
84. Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard JR. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol 2005; 175(7): 4189-93.
85. Ellermann-Eriksen S. Macrophages and cytokines in the early defence against herpes simplex virus. Virol J 2005; 2: 59.
86. Minami M, Kita M, Yan XQ, Yamamoto T, Iida T, Sekikawa K, et al. Role of IFN-gamma and tumor necrosis factor-alpha in herpes simplex. virus type 1 infection. J Interferon Cytokine Res 2002; 22(6): 671-6.
87. Feduchi E, Alonso MA, Carrasco L. Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol 1989; 63(3): 1354-9.
88. Croen KD. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J Clin Invest 1993; 91(6): 2446-52.
89. Fawaz LM, Sharif-Askari E, Menezes J. Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study. J Immunol 1999; 163(8): 4473-80.
90. Ahmad A, Sharif-Askari E, Fawaz L, Menezes J. Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity [i via interleukin-15 induction. J Virol 2000; 74(16): 7196-203.
91. Harris N, Buller RM, Karupiah G. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J Virol 1995; 69(2): 910-5.
92. Ghiasi H, Cai S, Slanina SM, Perng GC, Nesburn AB, Wechsler SL. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J Infect Dis 1999; 179(5): 1086-93.
93. Fujioka N, Akazawa R, Ohashi K, Fujii M, Ikeda M, Kurimoto M. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. J Virol 1999; 73(3): 2401-9.
94. Melchjorsen J, Pedersen FS, Mogensen SC, Paludan SR. Herpes simplex virus selectively induces expression of the CC chemokine RANTES/CCL5 in macrophages through a mechanism dependent on PKR and ICP0. J Virol 2002; 76(6): 2780-8.
95. Ghiasi H, Wechsler SL, Kaiwar R, Nesburn AB, Hofman FM. Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1. J Virol 1995; 69(1): 334-40.
96. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003; 16(1): 96-113.
97. Kuklin NA, Daheshia M, Chun S, Rouse BT. Role of mucosal immunity in herpes simplex virus infection. J Immunol 1998; 160(12): 5998-6003.
98. Jackson CG, Ochs HD, Wedgwood RJ. Immune response of a patient with deficiency of the fourth component of complement and systemic lupus erythematosus. N Engl J Med 1979; 300(20): 1124-9.
99. Peng T, Ponce-de-Leon M, Jiang H, Dubin G, Lubinski JM, Eisenberg RJ, et al. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. J Virol 1998; 72(1): 65-72.
100. Dudley KL, Bourne N, Milligan GN. Immune protection against HSV-2 in B-cell-deficient mice. Virology 2000; 270(2): 454-63.
101. Bamdad T, Roostaee MH, Sadeghizadeh M, Mahboudi F, Kazemnejad A, Soleimanjahi H. Immunogenicity and protective effect of a DNA construct encoding certain neutralizing epitopes of herpes simplex virus type-1 glycoprotein B. Folia Biol (Praha) 2005; 51(4): 109-13.
102. Kohl S. Role of antibody-dependent cellular cytotoxicity in neonatal infection with herpes simplex virus. Rev Infect Dis 1991; 13 (Suppl 11): S950-2.
103. Nash AA, Leung KN, Wildy P. The T cell mediated immune response of mice to herpes simplex virus. In: Lopez C, Roizman B, Eds. The Herpesviruses. New York: Plenum Press 1985; 87-102.
104. Sethi KK, Omata Y, Schneweis KE. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes. J Gen Virol 1983; 64 (Pt 2): 443-7.
105. Schmid DS, Rouse BT. The role of T cell immunity in control of herpes simplex virus. Curr Top Microbiol Immunol 1992; 179: 57-74.
106. Schmid DS, Mawle AC. T cell responses to herpes simplex viruses in humans. Rev Infect Dis 1991; 13(Suppl 11): S946-9.
107. Banerjee K, Biswas PS, Kumaraguru U, Schoenberger SP, Rouse BT. Protective and pathological roles of virus-specific and by-stander CD8+ T cells in herpetic stromal keratitis. J Immunol 2004; 173(12): 7575-83.
108. Banks TA, Nair S, Rouse BT. Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. J Virol 1993; 67(1): 613-6.
109. Banks TA, Allen EM, Dasgupta S, Sandri-Goldin R, Rouse BT. Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize immediate-early protein ICP27. J Virol 1991; 65(6): 3185-91.
110. Rouse RJ, Nair SK, Lydy SL, Bowen JC, Rouse BT. Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol 1994; 68(9): 5685-9.
111. Manickan E, Francotte M, Kuklin N, Dewerchin M, Molitor C, Gheysen D, et al. Vaccination with recombinant vaccinia, viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J Virol 1995; 69(8): 4711-6.
112. Tizard ML, Chan WL. Differential T cell response induced by certain recombinant oligopeptides of herpes simplex virus glycoprotein B in mice. J Gen Virol 1997; 78 (Pt 7): 1625-32.
113. Mueller SN, Jones CM, Chen W, Kawaoka Y, Castrucci MR, Heath WR, et al. The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells. J Virol 2003; 77(4): 2445-51.
114. Wallace ME, Keating R, Heath WR, Carbone FR. The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J Virol 1999; 73(9): 7619-26.
115. Glorioso J, Kees U, Kumel G, Kirchner H, Krammer PH. Identification of herpes simplex virus type 1 (HSV-1) glycoprotein gC as the immunodominant antigen for HSV-1-specific memory cytotoxic T lymphocytes. J Immunol 1985; 135(1): 575-82.
116. Sciammas R, Kodukula P, Tang Q, Hendricks RL, Bluestone JA. T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis. J Exp Med 1997; 185(11): 1969-75.
117. Irie H, Harada Y, Kataoka M, Nagamuta M, Moriya Y, Hands M, et al. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine. J Virol 1992; 66(4): 2428-34.
118. Streilein JW, Dana MR, Ksander BR. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol Today 1997; 18(9): 443-9.
119. Koelle DM, Ghiasi H. Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Curr Eye Res 2005; 30(11): 929-42.
120. Arvin AM. Live attenuated varicella vaccine. Pediatr Ann 1997; 26(6): 384-8.
121. Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M, et al. Outbreak of varicella, at a day-care center despite vaccination. N Engl J Med 2002; 347(24): 1909-15.
122. Mori I, Liu B, Goshima F, Ito H, Koide N, Yoshida T, et al. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2. Microbes Infect 2005; 7(15): 1492-500.
123. Sandstrom IK, Foster CS, Wells PA, Knipe D, Caron L, Greene MI. Previous immunization of mice with herpes simplex virus type-1 strain MP protects against secondary corneal infection. Clin Immunol Immunopathol 1986; 40(2): 326-34.
124. Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, Kern ER, et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 2005; 23(46-47): 5424-31.
125. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72(4): 3307-20.
126. Brehm M, Samaniego LA, Bonneau RH, DeLuca NA, Tevethia SS. Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0. Virology 1999; 256(2): 258-69.
127. Bert replication-incompetent HSV-1-based vectors. Gene Ther 2005; 12 (Suppl 1): S98-102.
128. Geiss BJ, Smith TJ, Leib DA, Morrison LA. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain. J Virol 2000; 74(23): 11137-44.
129. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006; 344(1): 230-9.
130. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 2000; 74(17): 7963-71.
131. McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994; 170(5): 1100-9.
132. Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997; 175(1): 16-25.
133. Franchini M, Abril C, Schwerdel C, Ruedl C, Ackermann M, Suter M. Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus. J Virol 2001; 75(1): 83-9.
134. Rees RC, McArdle S, Mian S, Li G, Ahmad M, Parkinson R, et al. Disabled infectious single cycle-herpes simplex virus (DISC-HSV) as a vector for immunogene therapy of cancer. Curr Opin Mol Ther 2002; 4(1): 49-53.
135. Lauterbach H, Ried C, Epstein AL, Marconi P, Brocker T. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J Gen Virol 2005; 86(Pt 9): 2401-10.
136. Burke RL. Contemporary approaches to vaccination against herpes simplex virus. Curr Top Microbiol Inummol 1992; 179: 137-58.
137. Skinner GR, Davies JA, Dundarov S, Andonov P. Prevention of herpes genitalis by the 'Bulgarian' vaccine F.HSV-2V(PRK): preliminary clinical evidence. Croat Med J 2000; 41(4): 378-83.
138. Skinner GR, Fink C, Melling J, Wiblin C. Thornton B, Hallworth J, et al. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med Microbiol Immunol (Berl) 1992; 180(6): 305-20.
139. Weijer WJ, Drijfhout JW, Geerligs HJ, Bloemhoff W, Feijlbrief M, Bos CA, et al. Antibodies against synthetic peptides of herpes simplex virus type 1 glycoprotein D and their capability to neutralize viral infectivity in vitro. J Virol 1988; 62(2): 501-10.
140. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87(3A): 14S-20S.
141. Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999; 18(1-2): 57-67.
142. Manservigi R, Grossi MP, Gualandri R, Balboni PG, Marchini A, Rotola. A, et al. Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector. J Virol 1990; 64(1): 431-6.
143. Nesburn AB, Slanina S, Burke RL, Ghiasi H, Bahri S, Wechsler SL. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol 1998; 72(10): 7715-21.
144. Koelle DM, Schomogyi M, McClurkan C, Reymond SN, Chen HB. CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins. J Virol 2000; 74(23): 11422-5.
145. Kohl S, Charlebois ED, Sigouroudinia M, Goldbeck C, Hartog K, Sekulovich RE, et al. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J Infect Dis 2000; 181(1): 335-9.
146. Corey L, Langenberg; AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282(4): 331-40.
147. Ashley R, Mertz G, Clark H, Schick M, Salter D, Corey L. Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine. J Virol 1985; 56(2): 475-81.
148. Simms JR, Heath AW, Jennings R. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs. J Infect Dis 2000; 181(4): 1240-8.
149. Bonneau RH, Salvucci LA, Johnson DC, Tevethia SS. Epitope specificity of H-2Kb-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones. Virology 1993; 195(1): 62-70.
150. Eberle R, Courtney RJ. Topological distribution of virus-specific and cross-reactive antigenic determinants on the gB glycoprotein of the herpes simplex viruses. J Med Virol 1989; 27(4): 309-16.
151. Grammer SF, Sette A, Colon S, Walker L, Chesnut R. Identification of an HSV-1/HSV-2 cross-reactive T cell determinant. J Immunol 1990; 145(7): 2249-53.
152. Heilman CJ, Jr., Zweig M, Hampar B. Herpes simplex virus type 1 and 2 intracellular p40: type-specific and cross-reactive antigenic determinants on peptides generated by partial proteolysis. J Virol 1981; 40(2): 508-15.
153. Peetermans J. Factors affecting the stability of viral vaccines. Dev Biol Stand 1996; 87: 97-101.
154. Bernstein DI, Ashley RL, Stanberry LR, Myers MG. Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines. J Clin Microbiol 1990; 28(1): 11-5.
155. Moroziewicz D, Kaufman HL. Gene therapy with poxvirus vectors. Curr Opin Mol Ther 2005; 7(4): 317-25.
156. Paoletti E, Lipinskas BR, Samsonoff C, Mercer S, Panicali D. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci USA 1994; 81(1): 193-7.
157. Rooney JF, Wohlenberg CR, Moss B, Notkins AL. Live vaccinia virus recombinants expressing herpes simplex virus genes. Rev Infect Dis 1991; 13(Suppl 11): S898-903.
158. Aurelian L, Smith CC, Wachsman M, Paoletti E. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D. Rev Infect Dis 1991; 13(Suppl 11: S924-34.
159. Bernstein DI. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine 2000; 18(14): 1351-8.
160. Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen J. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1995; 69(12): 8109-13.
161. Chabalgoity JA, Khan CM, Nash AA, Hormaeche CE. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol Microbiol 1996; 19(4): 791-801.
162. Karem KL, Bowen J, Kuklin N, Rouse BT. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J Gen Virol 1997; 78 (Pt 2): 427-34.
163. Cardenas L, Clements JD. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev 1992; 5(3): 328-42.
164. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259(5102): 1745-9.
165. Manickan E, Yu Z, Rouse BT. DNA immunization of neonates induces immunity despite the presence of maternal antibody. J Clin Invest 1997; 100(9): 2371-5.
166. Cui FD, Asada H, Kishida T, Itokawa Y, Nakaya T, Ueda Y, et al. Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice. Gene Ther 2003; 10(25): 2059-66.
167. Frye TD, Chiou HC, Hull BE, Bigley NJ. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge. Arch Virol 2002; 147(9): 1747-59.
168. Haynes JR, Arrington 3, Dong L, Braun RP, Payne LG. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine 2006; 24(23): 5016-26.
169. Mester JC, Twomey TA, Tepe ET, Bernstein DI. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine 1999; 18(9-10): 875-83.
170. McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996; 93(21): 11414-20.
171. Shroff KE, Marcucci-Borges LA, de Bruin SJ, Winter LA, Tiberio L, Pachuk C, et al. Induction of HSV-gD2 specific CD4(+) cells in Peyer's patches and mucosal antibody responses in mice following DNA immunization by both parenteral and mucosal administration. Vaccine 1999; 18(3-4): 222-30.
172. Gebhard JR, Zhu J, Cao X, Minnick J, Araneo BA. DNA immunization utilizing a herpes simplex virus type 2 myogenic DNA vaccine protects mice from mortality and prevents genital herpes. Vaccine 2000; 18(17): 1837-46.
173. Strasser JE, Arnold RL, Pachuk C, Higgins TJ, Bernstein DI. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J Infect Dis 2000; 182(5): 1304-10.
174. Higgins TJ, Herold KM, Arnold RL, McElhiney SP, Shroff KE, Pachuk CJ. Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J Infect Dis 2000; 182(5): 1311-20.
175. Suter M, Lew AM, Grob P, Adema GJ, Ackermann M, Shortman K, et al. BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1. Proc Natl Acad Sci USA 1999; 96(22): 12697-702.
176. Cui Z. DNA vaccine. Adv Genet 2005; 54: 257-89.
177. Straus SE, Savarese B, Tigges M, Freifeld AG, Krause PR, Margolis DM, et al. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J Infect Dis 1993; 167(5): 1045-52.
178. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 2004; 11(Suppl 3): 161A-9A.
179. Cohen WA. Defense Department to start immunizing troops against anthrax. In: Defense Do, Ed. Department of Defense 1997; p. http://www.defenselink.mil/news/Dec1997/b12151997_bt679-97.html.
180. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996; 174(6): 1168-75.
181. Nesburn AB, Burke RL, Ghiasi H, Slanina S, Bahri S, Wechsler SL. Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J Virol 1994; 68(8): 5084-92.
182. Dupuis M, McDonald DM, Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 1999; 18(5-6): 434-9.
183. El-Ghorr AA, Williams RM, Heap C, Norval M. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol Med Microbiol 2000; 29(4): 255-61.
184. O'Hagan D, Goldbeck C, Ugozzoli M, Ott G, Burke RL. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine 1999; 17(18): 2229-36.
185. Tengvall S, Josefsson A, Holmgren J, Harandi AM. CpG oligode-oxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. J Reprod Immunol 2005; 68(1-2): 53-69.
186. Kuklin NA, Daheshia M, Marconi PC, Krisky DM, Rouse RJ, Glorioso JC, et al. Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines. Virology 1998; 240(2): 245-53
187. Sin JI, Kim JJ, Boyer JD, Ciccarelli RB, Higgins TJ, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999; 73(1): 501-9.
188. Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol 2000; 74(23): 11173-80.
189. Parker JN, Pfister LA, Quenelle D, Gillespie GY, Markert JM, Kern ER, et al. Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine 2006; 24(10): 1644-52.
190. Lee S, Gierynska M, Eo SK, Kuklin N, Rouse BT. Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes Infect 2003; 5(7): 571-8.
191. Sin JI, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 1999; 162(5): 2912-21.
192. Zhu M, Xu X, Liu H, Liu X, Wang S, Dong F, et al. Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant. J Med Microbiol 2003; 52(Pt 3): 223-8.
193. Eo SK, Lee S, Chun S, Rouse BT. Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines. J Virol 2001; 75(2): 569-78.
194. Sin JI, Kim JJ, Ugen KE, Ciccarelli RB, Higgins TJ, Weiner DB. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through codelivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur J Immunol 1998; 28(11): 3530-40.
195. Flo J, Beatriz Perez A, Tisminetzky S, Baralle F. Superiority of intramuscular route and full length glycoprotein D for DNA vaccination against herpes simplex 2. Enhancement of protection by the co-delivery of the GM-CSF gene. Vaccine 2000; 18(28): 3242-53.
196. Toka FN, Gierynska M, Rouse BT. Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1. J Virol 2003; 77(23): 12742-52.
197. Sin JI, Kim J, Pachuk C, Weiner DB. Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo. Clin Diagn Lab Immunol 2000; 7(5): 751-8.
198. Lang A, Nikolich-Zugich J. Development and migration of protective CD8+ T cells into the nervous system following ocular herpes simplex virus-1 infection. J Immunol 2005; 174(5): 2919-25.
199. Stanberry LR. Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol 1995; 3(6): 244-7.
200. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006; 24(7): 914-20.
201. Mohamedi SA, Heath AW, Jennings R. Therapeutic vaccination against HSV-2: influence of vaccine formulation on immune responses and protection in mice. Vaccine 2000; 18(17): 1778-92.
202. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999; 17(13-14): 1681-9.
203. Keadle TL, Morrison LA, Morris JL, Pepose JS, Stuart PM. Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection. J Virol 2002; 76(8): 3615-25.
204. Walker J, Laycock KA, Pepose JS, Leib DA. Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice. Vaccine 1998; 16(1): 6-8.
205. Nesburn AB, Burke RL, Ghiasi H, Slanina SM, Wechsler SL. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology 1998; 252(1): 200-9.
206. Suvas S, Azkur AK, Kim BS, Kumaraguru U, Rouse BT. CD4+CD25+ regulatory T cells control the severity of viral immunoinflammatory lesions. J Immunol 2004; 172(7): 4123-32.
207. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, Hohman P, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176(5): 1129-34.
208. Chen CC, Ron Y. New strategies for immune-mediated anti-viral drug and vaccine development. Curr Pharm Des 2006; 12(11): 1391-401.
209. Dezfouli S, Hatzinisiriou I, Ralph SJ. Use of cytokines in cancer vaccines/immunotherapy: recent developments improve survival rates for patients with metastatic malignancy. Curr Pharm Des 2005; 11(27): 3511-30.
210. Schang LM. Herpes simplex viruses in antiviral drug discovery. Curr Pharm Des 2006; 12(11): 1357-70.